New Daily Pill for Obesity Treatment Expected in Israel Post-Rosh Hashanah
Translated & summarized from Walla by baba
A new daily oral obesity pill, Foundayo (orforglipron), will launch in Israel on September 15, offering a convenient alternative to injectable treatments. Clinical trials showed significant weight loss and health improvements, though gastrointestinal side effects are possible.
The story in 5 lines · by baba
- New daily oral obesity pill Foundayo launching in Israel September 15.
- Drug showed 12.4% average weight loss in clinical trials.
- Offers simpler alternative to existing injectable obesity treatments.
- Intended for adults with obesity or overweight with medical conditions.
- Potential side effects include nausea, vomiting, and diarrhea.
A new daily oral medication for obesity treatment, named Foundayo (orforglipron), is slated for release in Israel on September 15, following the Rosh Hashanah holiday. Israel will be the fourth country globally to commercially market the drug, which offers a simpler alternative to injectable GLP-1 medications.
The pill can be taken daily without regard to food or drink and does not require refrigeration, simplifying its use. It will be available in six different dosages, with the highest doses potentially costing up to 1,146 shekels per month. The medication is intended for adults with obesity or overweight individuals with at least one weight-related medical condition, to be used in conjunction with a reduced-calorie diet and exercise.
Clinical trials demonstrated significant weight loss, with participants taking the highest dose losing an average of 12.4% of their body weight, approximately 12.4 kilograms. The drug also showed improvements in waist circumference, cholesterol levels, and blood pressure. In studies involving individuals with type 2 diabetes, improvements in blood sugar levels were also observed.
Dr. Raz Haguel, Director of the National Center for Obesity Treatment, highlighted the importance of expanding treatment options for chronic obesity, stating that the new pill provides an alternative for patients who prefer oral medication. He emphasized that having more choices allows for better tailoring of treatment to individual lifestyles and preferences, aiming for sustainable weight management.
Like other GLP-1 related treatments, Foundayo may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, particularly at the start of treatment. Approximately 10.6% of participants in clinical trials discontinued the medication due to these side effects. The drug has already received approval in the United States and the United Kingdom and is available in the UAE. Its submission for approval by the Israeli Ministry of Health and inclusion in the national health basket is pending.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 7Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.